A Phase 2 interventional study of Varilrix (inactivated varicella vaccine) in Varicella, sponsored by GlaxoSmithKline. Completed at 13 sites in 2 countries. Open to participants aged 11 Months to 21 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-08.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Chickenpox by GlaxoSmithKline — 6 open to participants now, 6 under way, 6 of them phase 3. Chickenpox · GlaxoSmithKline.
Among the 35 studies in Chickenpox by GlaxoSmithKline, this one is the 25th largest by enrollment of the 29 interventional ones that give a count, is one of 6 that started in 2007, is one of 11 in phase 2, and was the 15th registered.
180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.
Browse Chickenpox studies →6 of the 35 studies in Chickenpox by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 15 mo–6 yrs · Healthy volunteers
GlaxoSmithKline · Sites in Dominican Republic, Honduras
Ages 12 mo–15 mo · Healthy volunteers
GlaxoSmithKline · Sites in United States, Belgium, Estonia and 4 more countries
Ages 12 mo–15 mo · Healthy volunteers
GlaxoSmithKline · Sites in United States, Belgium, Colombia and 8 more countries
Ages 12 mo–15 mo · Healthy volunteers
GlaxoSmithKline · Sites in United States, Bulgaria, Denmark and 5 more countries
Ages 12 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 11 Months to 21 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 6 started in 2007.
This study's enrollment of 244 is below the median of 475 across 149 interventional studies indexed under Chickenpox.
Median enrollment 600 across the 29 interventional studies, 379 across the 5 observational. Of the 28 that completed or were terminated, 16 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
3 of the studies in Chickenpox by GlaxoSmithKline that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06693895Phase 3GlaxoSmithKlineA Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age | 2026-11-23 |
| NCT06806137Phase 3GlaxoSmithKlineA Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age | 2026-12-14 |
| NCT06740630Phase 3GlaxoSmithKlineA Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age | 2026-12-25 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Chickenpox by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate a modified formulation of GSK Biologicals' live attenuated varicella vaccine. In vivo pre-clinical data show this change has no negative impact on vaccine safety. This present study is undertaken to rule out any negative impact on the immunogenicity and safety of GSK Biologicals' live attenuated varicella virus vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine produced without human serum albumin (HSA-Free), administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
Biological: Varilrix (inactivated varicella vaccine)
Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine, administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
Biological: Varilrix (inactivated varicella vaccine)
subcutaneously injection
Antibody Titers Against Varicella Zoster Virus (VZV)
Antibody titers have been assessed by immunofluorescence assay (IFA) and presented as geometric mean titers (GMTs), for initially seronegative subjects \[with anti-VZV titer below (\<) 1:4\].
Time frame: At 43-57 days after the first vaccine dose (Week 6)
Antibody Concentrations Against Varicella Zoster Virus (VZV)
Antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), for initially seronegative subjects \[with anti-VZV concentration below (\<) 25 mIU/mL\].
Time frame: At 43-57 days after the first vaccine dose (Week 6)
Number of Seroconverted Subjects for Varicella Antibodies
Seroconversion/seroresponse (considering the IFA data) was defined as the appearance of anti-VZV antibodies \[i.e. titer/concentration greater than or equal to (≥) the assay cut-off value of 1:4\] in the sera of subjects who were seronegative before vaccination.
Time frame: At 43-57 days post-Dose 1 (Week 6) and 86-114 days post-Dose 2 (Week 12)
Number of Subjects With Anti-VZV Antibody Concentrations Above Cut-off Values
Anti-VZV antibody concentrations greater than or equal to (≥) the assay cut-off values of: 25 mIU/mL, 50 mIU/mL and 75 mIU/mL have been assesssed by ELISA, in the sera of subjects who were seronegative before vaccination.
Time frame: At 43-57 days post-Dose 1 (Week 6) and 86-114 days post-Dose 2 (Week 12)
Antibody Titers Against Varicella Zoster Virus (VZV)
Antibody titers have been assessed by immunofluorescence assay (IFA) and presented as geometric mean titers (GMTs), for initially seronegative subjects \[with anti-VZV titer below (\<) 1:4\].
Time frame: At 86-114 days after the second vaccine dose (Week 12)
Antibody Concentrations Against Varicella Zoster Virus (VZV)
Antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), for initially seronegative subjects \[with anti-VZV concentration below (\<) 25 mIU/mL\].
Time frame: At 86-114 days after the second vaccine dose (Week 12)
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.
Time frame: During the 4-day (Days 0-3) post-vaccination period following each dose
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fever \[defined as axillary fever ≥ 37.5 degrees Celsius (°C)\] and generalized rash. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 fever = temperature above (\>) 39.0°C after vaccination. Grade 3 rash = more than (\>) 150 lesions. Related = considered by the investigator to be causally related to the study vaccination.
Time frame: During the 43-day (Days 0-42) post-vaccination period following each dose
Number of Subjects With Any Unsolicited Adverse Event (AE)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.
Time frame: Within the 43-day (Days 0-42) post-vaccination period following each dose
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: From Day 0 up to study end (Day 86-114)
| Milestone | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| Started | 122 | 122 |
| Completed | 121 | 121 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
Antibody titers have been assessed by immunofluorescence assay (IFA) and presented as geometric mean titers (GMTs), for initially seronegative subjects \[with anti-VZV titer below (\<) 1:4\].
| Titers | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| Antibody Titers Against Varicella Zoster Virus (VZV) | 172.6 (141.6 to 210.3) | 154.3 (128.7 to 185) |
Antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), for initially seronegative subjects \[with anti-VZV concentration below (\<) 25 mIU/mL\].
| mIU/mL | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| Antibody Concentrations Against Varicella Zoster Virus (VZV) | 123.5 (107.9 to 141.4) | 110.7 (98.4 to 124.6) |
Seroconversion/seroresponse (considering the IFA data) was defined as the appearance of anti-VZV antibodies \[i.e. titer/concentration greater than or equal to (≥) the assay cut-off value of 1:4\] in the sera of subjects who were seronegative before vaccination.
| Participants | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| Anti-VZV, Week 6 | 114 | 114 |
| Anti-VZV, Week 12 | 115 | 112 |
Anti-VZV antibody concentrations greater than or equal to (≥) the assay cut-off values of: 25 mIU/mL, 50 mIU/mL and 75 mIU/mL have been assesssed by ELISA, in the sera of subjects who were seronegative before vaccination.
| Participants | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| Anti-VZV ≥ 25 mIU/mL, Week 6 | 114 | 113 |
| Anti-VZV ≥ 25 mIU/mL, Week 12 | 116 | 114 |
| Anti-VZV ≥ 50 mIU/mL, Week 6 | 105 | 103 |
| Anti-VZV ≥ 50 mIU/mL, Week 12 | 116 | 114 |
| Anti-VZV ≥ 75 mIU/mL, Week 6 | 89 | 89 |
| Anti-VZV ≥ 75 mIU/mL, Week 12 | 116 | 114 |
Antibody titers have been assessed by immunofluorescence assay (IFA) and presented as geometric mean titers (GMTs), for initially seronegative subjects \[with anti-VZV titer below (\<) 1:4\].
| Titers | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| Antibody Titers Against Varicella Zoster Virus (VZV) | 1452.5 (1240.7 to 1700.5) | 1395.4 (1183 to 1645.9) |
Antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), for initially seronegative subjects \[with anti-VZV concentration below (\<) 25 mIU/mL\].
| mIU/mL | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| Antibody Concentrations Against Varicella Zoster Virus (VZV) | 1013.6 (880.9 to 1166.4) | 999.2 (877.3 to 1138.1) |
Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.
| Participants | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| Any Pain, Dose 1 | 13 | 15 |
| Grade 3 Pain, Dose 1 | 0 | 0 |
| Any Redness, Dose 1 | 33 | 34 |
| Grade 3 Redness, Dose 1 | 0 | 0 |
| Any Swelling, Dose 1 | 5 | 7 |
| Grade 3 Swelling, Dose 1 | 0 | 0 |
| Any Pain, Dose 2 | 23 | 18 |
| Grade 3 Pain, Dose 2 | 0 | 0 |
| Any Redness, Dose 2 | 44 | 46 |
| Grade 3 Redness, Dose 2 | 6 | 3 |
| Any Swelling, Dose 2 | 18 | 14 |
| Grade 3 Swelling, Dose 2 | 2 | 2 |
Assessed solicited general symptoms were fever \[defined as axillary fever ≥ 37.5 degrees Celsius (°C)\] and generalized rash. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 fever = temperature above (\>) 39.0°C after vaccination. Grade 3 rash = more than (\>) 150 lesions. Related = considered by the investigator to be causally related to the study vaccination.
| Participants | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| Any Temperature, Dose 1 | 64 | 52 |
| Grade 3 Temperature, Dose 1 | 13 | 11 |
| Related Temperature, Dose 1 | 2 | 2 |
| Any Rash, Dose 1 | 1 | 0 |
| Grade 3 Rash, Dose 1 | 54 | 53 |
| Related Rash, Dose 1 | 6 | 12 |
| Any Temperature, Dose 2 | 3 | 3 |
| Grade 3 Temperature, Dose 2 | 1 | 0 |
| Related Temperature, Dose 2 | 31 | 18 |
| Any Rash, Dose 2 | 0 | 0 |
| Grade 3 Rash, Dose 2 | 31 | 23 |
| Related Rash, Dose 2 | 1 | 0 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.
| Participants | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| Any AE(s), Dose 1 | 56 | 45 |
| Any AE(s), Dose 2 | 35 | 42 |
Serious adverse events (SAEs) assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.
| Participants | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 2 | 5 |
Collected over Solicited local symptoms: during the 4-day (Days 0-3) post each dose. Solicited general symptoms and unsolicited AEs: during the 43-day (Days 0-42) post each dose. SAEs: during the entire study period (Day 0 to Day 86/114).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varilrix HSA-Free Group | 0/122 (0%) | 2/122 (1.6%) | 103/122 (84.4%) |
| Varilrix Group | 0/122 (0%) | 5/122 (4.1%) | 100/122 (82%) |
| Event | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| ConcussionInjury, poisoning and procedural complications | 0/122 | 1/122 |
| Breath holdingPsychiatric disorders | 0/122 | 1/122 |
| Otitis mediaInfections and infestations | 1/122 | 1/122 |
| BronchitisInfections and infestations | 0/122 | 1/122 |
| GastroenteritisInfections and infestations | 1/122 | 0/122 |
| LaryngitisInfections and infestations | 0/122 | 1/122 |
| MastoiditisInfections and infestations | 0/122 | 1/122 |
| SinusitisInfections and infestations | 0/122 | 1/122 |
| Event | Varilrix HSA-Free Group | Varilrix Group |
|---|---|---|
| Fever (Dose 1)General disorders | 64/121 | 52/122 |
| Fever (Dose 2)General disorders | 54/121 | 53/121 |
| Redness (Dose 2)General disorders | 44/121 | 46/121 |
| Redness (Dose 1)General disorders | 33/121 | 34/122 |
| Pain (Dose 2)General disorders | 23/121 | 18/121 |
| Swelling (Dose 2)General disorders | 18/121 | 14/121 |
| Pain (Dose 1)General disorders | 13/121 | 15/122 |
| Bronchitis (Dose 1)Infections and infestations | 15/122 | 8/122 |
| Viral infection (Dose 2)Infections and infestations | 6/121 | 13/121 |
| Bronchitis (Dose 2)Infections and infestations | 8/121 | 11/121 |
| Age, Continuous(Months) | Varilrix HSA-Free Group | Varilrix Group | Total |
|---|---|---|---|
| Mean | 15.6 ± 3.34 | 14.8 ± 3.08 | 15.20 ± 3.23 |
| Sex: Female, Male(Participants) | Varilrix HSA-Free Group | Varilrix Group | Total |
|---|---|---|---|
| Female | 59 | 60 | 119 |
| Male | 63 | 62 | 125 |
| Race/Ethnicity, Customized(Participants) | Varilrix HSA-Free Group | Varilrix Group | Total |
|---|---|---|---|
| White-Caucasian/European heritage | 122 | 122 | 244 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Nov 2007 to primary completion in Mar 2008, 4 months.
Results were first posted in Jun 2017, 9 years 3 months after primary completion.
Of 17 phase 2 interventional studies under Chickenpox, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.